-
2024-510616-73-00
5
2020-12-16
newly diagnosed WHO grade 2 or 3 glioma
-
2024-513950-32-00
4
2020-12-15
Intermediate stage hepatocellular carcinoma (HCC)
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-515114-41-00
7
2020-08-10
Solid tumors
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2024-516741-39-00
6
2020-01-14
Haemophilia A
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-507689-26-00
5
2019-10-07
Histologically or cytologically confirmed Locoregional Hepatocellular
-
2024-510964-21-00
9
2019-09-12
Glioblastoma
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-514556-32-00
5
2017-02-15
Adult critically ill patients with severe vitamin D deficiency
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2025-520775-81-00
5
2025-12-23
Short Bowel Syndrome
-
2024-517524-18-00
10
2025-10-22
Patients with moderate-to-severe allergic rhinitis / rhinoconjunctivit
-
2024-517521-25-00
10
2025-10-20
Patients with moderate-to-severe allergic rhinitis/rhinoconjunctivitis
-
2024-511452-40-00
10
2025-09-12
Oncology - Glioblastoma (GBM)
-
2024-517515-75-00
10
2025-07-17
Patients with moderate-to-severe allergic rhinitis / rhinoconjunctivit
-
2024-513282-39-00
5
2025-05-28
Hidradenitis Suppurativa (HS)
-
2024-513210-36-00
5
2025-04-04
Chronic Spontaneous Urticaria
-
2024-515022-88-00
5
2025-03-03
Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA